Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally disease progression or perhaps the contributors are unable to tolerate the study drugs.For all circulation cytometry experiments, ten,000 cells for each replicate were a